ArticleEmerging microbes & infections2026
Live-attenuated African swine fever vaccine HLJ/18-7GD is safe in pregnant sows with no impact on reproductive performance or offspring health at a field farm.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- MGF100 but not MGF300 family is a potential multigene-deleted target for ASFV attenuation and live attenuated vaccine development.Virulence · 2026Article
- African swine fever in the era of global expansion: Epidemiology, transmission dynamics, viral evolution, and One Health control strategies.Veterinary world · 2026Review
- Live-Attenuated Vaccines Against African Swine Fever: Strategies, Lessons, and Prospects.Biology · 2026Review
- Current Insights into the Epidemiology and Transmission Dynamics of African Swine Fever Virus and Future Control Perspectives.Pathogens (Basel, Switzerland) · 2026Review
- African Swine Fever: Vaccine Advancement and Major Gaps.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) continues to pose a threat to the global pig industry. Previously, we generated a Georgia-07-like genotype II African swine fever virus (ASFV)-based gene-deleted live vaccine (HLJ/18-7GD) and demonstrated that it is safe for pigs and pregnant sows and effective against the parent virus in the laboratory. Here, we report a systematic field safety assessment of HLJ/18-7GD in 201 sows and their offspring across two parities in a real-world farm scenario performed over more than 11 months. Pregnant sows inoculated with HLJ/18-7GD presented no disease signs or adverse reactions and no changes in gestational status or reproductive performance. Inoculation of sows with HLJ/18-7GD did not affect the health, growth or fattening of first- or second- parity offspring. HLJ/18-7GD was detected in inoculated sows and some first-parity piglets but not in second-parity piglets. The vaccine replicated at low levels in sows and their offspring and was cleared in sows by 84 days post inoculation and at age 56 days in first-parity piglets. These data further demonstrate that HLJ/18-7GD is safe for pregnant sows and their offspring, providing strong evidence that the development of gene-deleted live attenuated vaccines is a feasible strategy for obtaining safe and efficacious vaccines against ASF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.